Drug Information Association Logo

Anti-Doping Community

Already a Member? Visit this Community      
Not a Community Member? Join

Chairperson. Barbara Leishman, F. Hoffmann-La Roche Ltd.


  • To foster awareness of the risks posed by misuse of medicines for performance enhancement in sport and to support efforts by industry to mitigate these risks
  • To develop and refine effective models for collaboration between the biopharmaceutical industry and anti-doping agencies
  • To exchange practical experience in collaborating with WADA (e.g. assessment guidelines, templates for documents such as a Memorandum of Agreement
  • To foster understanding of the perspectives of all stakeholders (industry, regulatory agencies, WADA)
  • To stay abreast of latest regulatory developments

Take advantage of all the benefits of membership.

Become a DIA Member


Manage My Community Memberships